{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:55:17Z","timestamp":1769482517011,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dermatomyositis (DM) is an autoimmune myopathy often linked to aberrant type I interferon (IFN) pathway activation. However, the molecular mediators driving this IFN signature and their utility as biomarkers remain incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an integrated multi-omics analysis combining plasma proteomics from 14 patients with DM and 5 healthy controls, with transcriptomic profiling of skeletal muscle derived from three publicly available Gene Expression Omnibus datasets (GSE11971, GSE1551, and GSE128470). Selected plasma proteins were further quantified and validated using enzyme-linked immunosorbent assay (ELISA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Proteomic profiling identified 482 differentially expressed proteins (DEPs). Upregulated DEPs were enriched in antiviral responses and IFN-related immune pathways, while downregulated DEPs were associated with extracellular matrix organization. Transcriptomic analysis revealed 156 consistently upregulated differentially expressed genes across datasets, primarily involved in innate immunity, nucleic acid sensing, and antigen presentation. Integrative analysis identified 2\u2032-5\u2032-oligoadenylate synthetase 3 (OAS3) as a central hub within the IFN signaling network. ELISA validation demonstrated significantly elevated plasma OAS3 levels in DM patients (median: 5.073 ng\/ml, IQR: 2.93\u20139.36) compared with controls (median: 2.723 ng\/mL, IQR: 1.77\u20133.34), with a P-value of 0.018. Notably, plasma OAS3 levels showed a positive correlation with serum creatine kinase concentrations (r=0.55, P = 0.044).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OAS3 expression was consistently elevated in both plasma and skeletal muscle tissues of individuals with DM. This molecule may act as a key enhancer of type I IFN-mediated pathogenic responses. Our results support the potential of OAS3 as a novel biomarker and therapeutic target in DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1735236","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:40:59Z","timestamp":1769406059000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated proteomic and transcriptomic profiles reveals the role of OAS3 in dermatomyositis pathogenesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhuangzhuang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Neurovascular Disease Discovery","place":["Beijing, China"]},{"name":"Rare Diseases Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjun","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Neurovascular Disease Discovery","place":["Beijing, China"]},{"name":"Rare Diseases Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Neurovascular Disease Discovery","place":["Beijing, China"]},{"name":"Rare Diseases Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Neurovascular Disease Discovery","place":["Beijing, China"]},{"name":"Rare Diseases Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Neurovascular Disease Discovery","place":["Beijing, China"]},{"name":"Rare Diseases Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Neurovascular Disease Discovery","place":["Beijing, China"]},{"name":"Rare Diseases Medical Center, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and Dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2011.01.001","article-title":"Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features","volume":"37","author":"Khan","year":"2011","journal-title":"Rheum Dis Clinics North America"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24786","article-title":"Incidence, prevalence, and mortality of dermatomyositis: A population-based cohort study","volume":"75","author":"Kronzer","year":"2023","journal-title":"Arthritis Care Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04910-w","article-title":"Mortality of Chinese patients with polymyositis and dermatomyositis","volume":"39","author":"Yang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100018","article-title":"Polymyositis and dermatomyositis \u2013 challenges in diagnosis and management","volume":"2","author":"Yang","year":"2019","journal-title":"J Trans Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e156025","DOI":"10.1172\/JCI156025","article-title":"Using autoantibody signatures to define cancer risk in dermatomyositis","volume":"132","author":"Turnier","year":"2022","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"151940","DOI":"10.1016\/j.semarthrit.2021.12.008","article-title":"Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center","volume":"53","author":"Trallero-Aragu\u00e1s","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.021","article-title":"Using multi-omics methods to understand dermatomyositis\/polymyositis","volume":"16","author":"Gao","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103686","article-title":"The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis","volume":"23","author":"Castellini","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21775\/cimb.040.221","article-title":"OASs in defense of mycobacterial infection: angels or demons","volume":"40","author":"Zhang","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-023-03052-4","article-title":"Identification of key biomarkers associated with immune cells infiltration for myocardial injury in dermatomyositis by integrated bioinformatics analysis","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S416493","article-title":"TRIM5 promotes systemic lupus erythematosus through CD4(+) T cells and macrophage","volume":"16","author":"Pan","year":"2023","journal-title":"IJGM"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.jid.2022.02.018","article-title":"OAS1, OAS2, and OAS3 contribute to epidermal keratinocyte proliferation by regulating cell cycle and augmenting IFN-1\u2013Induced jak1\u2013Signal transducer and activator of transcription 1 phosphorylation in psoriasis","volume":"142","author":"Huang","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromusc Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2018.4256","article-title":"Discovery of key genes in dermatomyositis based on the gene expression omnibus database","volume":"37","author":"Xie","year":"2018","journal-title":"DNA Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead597","article-title":"Single-cell landscape of peripheral immune response in patients with anti-melanoma differentiation\u2013associated gene 5 dermatomyositis","volume":"63","author":"He","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821f440a","article-title":"Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies","volume":"76","author":"Cappelletti","year":"2011","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-016-1033-y","article-title":"Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents","volume":"18","author":"Loell","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells14120939","article-title":"Muscle spatial transcriptomic reveals heterogeneous profiles in juvenile dermatomyositis and persistence of abnormal signature after remission","volume":"14","author":"Tragin","year":"2025","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00856-14","article-title":"Cell-type-specific effects of RNase L on viral induction of beta interferon","volume":"5","author":"Banerjee","year":"2014","journal-title":"mBio"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519657113","article-title":"Activation of RNase L is dependent on OAS3 expression during infection with diverse human viruses","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092786","article-title":"Expression of the OAS gene family is highly modulated in subjects affected by juvenile dermatomyositis, resembling an immune response to a dsRNA virus infection","volume":"19","author":"Musumeci","year":"2018","journal-title":"IJMS"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113998","article-title":"Initiation of a ZAK\u03b1-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L","volume":"43","author":"Xi","year":"2024","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e9292","DOI":"10.1590\/1414-431x20209292","article-title":"MALAT1 is involved in type I IFNs-mediated systemic lupus erythematosus by up-regulating OAS2, OAS3, and OASL","volume":"53","author":"Gao","year":"2020","journal-title":"Braz J Med Biol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0807265105","article-title":"An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity","volume":"105","author":"Li","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382728","article-title":"Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152426","article-title":"Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature","volume":"66","author":"Sener","year":"2024","journal-title":"Semin Arthritis Rheum"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735236\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:41:01Z","timestamp":1769406061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735236\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1735236"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735236","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1735236"}}